Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Evaluation of breast cancer PDX tumor heterogeneity

ABSTRACT: Evaluation of breast cancer PDX tumor heterogeneity

PROVIDER: PRJNA984700 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR24968700_1.fastq.gz	Fastqsanger.gz
	SRR24968700_2.fastq.gz	Fastqsanger.gz
	SRR24968800_1.fastq.gz	Fastqsanger.gz
	SRR24968800_2.fastq.gz	Fastqsanger.gz
	SRR24968701_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 592

Similar Datasets

Evaluation of breast cancer PDX tumor heterogeneity at single cell resolution II

Project description:Evaluation of breast cancer PDX tumor heterogeneity at single cell resolution II

| PRJNA1158224 | ENA

Evaluation of breast cancer PDX tumor heterogeneity at single cell resolution [scRNA-seq]

Project description:Evaluation of breast cancer PDX tumor heterogeneity at single cell resolution [scRNA-seq]

| PRJNA985573 | ENA

Evaluation of breast cancer PDX tumor heterogeneity at single cell resolution II

Project description:Breast cancer is the most commonly diagnosed cancer among women. PDXs (patient-derived xenografts) are similar to cancer cell lines but differ in that they are maintained in a physiological setting as soon as they are isolated from the patient and for subsequent passages. These models are valuable for preclinical trials because PDX models have been shown to closely match their patient counterparts, both in genomic profile and response to treatment. One challenge to treatment development is tumor heterogeneity. In this study, we profiled ER+ and triple negative breast cancer PDX models using single-cell RNA-sequencing. This data may help identify populations of cells which are susceptible to certain treatments in order to improve clinical outcomes for breast cancer patients.

2024-09-30 | GSE276609 | GEO

Evaluation of breast cancer PDX tumor heterogeneity at single cell resolution [scRNA-seq]

2023-07-18 | GSE235168 | GEO

Evaluation of breast cancer PDX tumor heterogeneity

Project description:This SuperSeries is composed of the SubSeries listed below.

2023-07-18 | GSE235169 | GEO

Epigenetic heterogeneity and transcriptional drivers of triple-negative breast cancer (PDX Methylation)

Project description:Epigenetic heterogeneity and transcriptional drivers of triple-negative breast cancer (PDX Methylation)

| PRJNA837239 | ENA

Expression data from Patient-derived tumor models (PDX) establish from bone metastases and match human breast primary tumor.

Project description:A significant proportion of patients with oestrogen receptor (ER) positive breast cancers (BC) develop resistance to endocrine treatments (ET) and relapse with metastatic disease. Bone is the most common metastatic site in ER+ patients, however bone metastases are technically challenging to biopsy and analyse. Difficulties concern both tumour tissue acquisition and techniques for analysis and RNA extractions. Patient-derived xenografts (PDX) of BC bone metastases have not been reported yet. For the first time we established PDX models from bone metastatic biopsies of patients progressing on ET and treated by vertebroplasty. PDX models were analysed at transcriptomic level and compared to patient’s early primary tumours to identify new therapeutic targets associated with endocrine resistance in the metastatic setting. Identification of activated signalling pathways in bone metastasis by comparative transcriptomic analyses of the bone metastasis derived PDX compared to the patients' primary breast tumor.

2020-06-29 | GSE146661 | GEO

RNA sequencing of luminal breast cancer patient-derived xenografts (PDX) library to capture tumor heterogeneity and explore the mechanisms of resistance to CDK4/6 inhibitors

Project description:Combining CDK4/6 inhibitors (CDK4/6i) with endocrine therapy has proven clinically effective and represents now the first-line treatment for advanced Luminal Breast Cancer (LBC) patients. However, resistance to CDK4/6i almost invariably arises in these patients, emphasising the critical need to comprehend these mechanisms and develop new strategies to overcome resistance. We report on the generation and characterisation of a LBC PDX displaying acquired resistance to CDK4/6i palbociclib. Treating a sensitive luminal BC PDX with the CDK4/6i palbociclib revealed that, despite initial tumour shrinkage, some tumours might eventually regrow under drug treatment. RNA sequencing, followed by gene set enrichment analyses, unveiled that this PDX have become refractory to CDK4/6i, both at biological and molecular level.

2024-11-18 | E-MTAB-14085 | biostudies-arrayexpress

Heterogeneity of Breast Cancer Vasculature

Project description:Tumor-associated breast vasculature was laser-cappture microdissected from IDC breast cancer cases. The goal of the study was to characterize the heterogeneity of breast tumor-associated vasculature and identify gene expression signatures predictive of clinical outcome. common reference design, 32 samples

2010-09-19 | E-GEOD-15363 | biostudies-arrayexpress

Epigenetic heterogeneity and transcriptional drivers of triple-negative breast cancer (PDX RNA-Seq)

Project description:Epigenetic heterogeneity and transcriptional drivers of triple-negative breast cancer (PDX RNA-Seq)

| PRJNA837241 | ENA